Notice of Annual General Meeting Share sub-division 27 April 2021 - London, UK - Crossword Cybersecurity Plc (AIM:CCS, Crossword , the Company or the Group ), the technology commercialisation company focused on cyber security and risk management, is pleased to announce its final results for the year ended 31 December 2020. The Notice of its Annual General meeting ( AGM ) and a Form of Proxy will be posted to Shareholders shortly. A copy of the Annual Report and Accounts and the notice of AGM are available on the Company s website at www.crosswordcybersecurity.com . AGM and Investor Meeting The AGM will be held on Tuesday 25 May 2021 at 3.00pm at the Company s offices, Capital Tower, 91 Waterloo Road, London SE1 8RT, United Kingdom. The health and safety of our Shareholders and colleagues is always our utmost priority.
People on the move: 31 top North West appointments you may have missed
With lockdowns easing and business confidence recovering, firms across the region have wasted no time in making key hires
Chris Capes, Lauren Wilden, Ian Chatburn and Jess Shepherd are among recent North West appointments
Sign up to FREE email alerts from BusinessLive North WestInvalid EmailSomething went wrong, please try again later.
Subscribe
When you subscribe we will use the information you provide to send you these newsletters. Your information will be used in accordance with ourPrivacy Notice.
Thank you for subscribingWe have more newslettersShow meSee ourprivacy notice
With Covid lockdowns easing and business confidence recovering, firms from across the North West have wasted no time recently in making a host of key hires.
7.0% Adj. ebitda margin Pre-IFRS 16 ü In Q1 2021, X5 delivered 8.1% year-on-year (y-o-y) revenue growth driven by a 6.4% rise in offline sales and a 1.7% contribution from increasing digital businesses sales, which rose 363.5% y-o-y to RUB 10.5 billion and comprised 2.1% of consolidated revenue. ü Gross margin (2) under IFRS 16 improved by 82 b.p. y-o-y (by 81 b.p. pre-IFRS 16 (3) ) in Q1 2021, driven predominantly by better shrinkage and logistics costs as a result of operating improvements and higher commercial margin due to reduced price investments. ü SG&A expenses excluding D&A&I, LTI, other one-off share-based payments and the impact of the Karusel transformation increased by 113 b.p. of revenue under IFRS 16 (up by 109 b.p. pre-IFRS 16), on the back of staff costs, utilities, third party services and other expenses.
London, UK - 27 April 2021: Oxford Biomedica plc ( Oxford Biomedica , the Company or the Group ) (LSE:OXB), a leading gene and cell therapy group, gives notice that copies of the 2020 Annual report and accounts and the Notice of Annual General Meeting ( AGM ) have been sent to shareholders. These documents are available on the Investors section of the Group s website at www.oxb.com . Oxford Biomedica plc announced its preliminary results for the year ended 31 December 2020 on 15 April 2021. Copies of these documents have been submitted to the Financial Conduct Authority for publication through the National Storage Mechanism and will shortly be available for inspection at https://data.fca.org.uk/#/nsm/nationalstoragemechanism.
Continued NAV progression and balance sheet strength · EPRA NAV per share increased by 0.8% to 109.1 pence (31 December 2020: 108.2 pence) reflecting improved earnings and valuation uplifts across the portfolio from modest yield tightening and annual rental uplifts · NAV total return (including dividend) of 2.5% for the quarter · Substantially oversubscribed placing raised gross proceeds of £60 million, with strong support from existing and new shareholders. The targeted size of the placing was increased from £50 million during the marketing period due to investor demand and strong acquisition pipeline visibility · Available cash & undrawn debt totalled £132.6 million, with a low net loan-to-value ( LTV ) of 13.4% providing significant operational flexibility. All proceeds from the equity placing have been allocated to acquisitions under non-binding heads-of-terms, and in the meantime have been used to tempora